Methylcobalamin injection recalled due to sterility assurance concerns
Red Mountain Compounding Pharmacy is recalling a methylcobalamin injectable solution after FDA inspection raised concerns about the lack of assurance of sterility.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall. The source text indicates a sterility assurance concern raised during inspection but does not report any actual illnesses, injuries, or adverse events. The hazard is investigational/precautionary rather than confirmed.
Plain-English summary
First Royal Care Co. LLC, operating as Red Mountain Compounding Pharmacy, is recalling METHYLCOBALAMIN 12.5MG/ML MDV (multi-dose vial) injectable solution, prescription only. The recall was initiated following an FDA inspection that raised sterility assurance concerns regarding the product.
The product was distributed to 494 patients/consumers who received prescriptions. Distribution occurred across Arizona, California, Florida, Minnesota, Montana, Texas, and Utah. All affected lots are still within expiration dating.
Consumers who have received this product should consult their healthcare provider or pharmacist regarding continued use of the recalled medication. The lack of adequate sterility assurance in an injectable solution poses a potential risk that should be addressed with medical guidance.
The recalled product
- Product
- METHYLCOBALAMIN 12.5MG/ML MDV INJ SOLN, Rx only, Red Mountain Compounding Rx
- Manufacturer
- First Royal Care Co. LLC, dba Red Mountain Compounding Pharmacy
- Hazard
- sterility-assurance
- injectable-contamination-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- all lots within expiry
Distribution
Distributed in 7 states:
- AZ
- CA
- FL
- MN
- MT
- TX
- UT
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- ModerateGas-X Simethicone 125 mg softgels recall for incomplete labeling
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27